Starpharma Holdings Ltd. buy Subdi
Start price
29.03.20
/
50%
€0.42
Target price
24.10.24
€1.80
Performance (%)
-82.78%
End price
16.11.23
€0.072
Summary
This prediction ended on 16.11.23 with a price of €0.072. The BUY prediction by Subdi for Starpharma Holdings Ltd. performed very badly with a performance of -82.78%. Subdi has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Starpharma Holdings Ltd. | 6.818% | 6.818% | -75.690% | -93.349% |
| iShares Core DAX® | 2.112% | -0.367% | 13.466% | 16.854% |
| iShares Nasdaq 100 | -2.197% | -3.794% | 38.426% | 42.934% |
| iShares Nikkei 225® | -1.555% | -7.320% | 18.451% | 2.941% |
| iShares S&P 500 | -0.472% | -2.078% | 27.488% | 41.955% |
Comments by Subdi for this prediction
In the thread Starpharma Holdings Ltd. diskutieren
Gute Aussichten:
Starpharma: Beaten Up By COVID-19 For No Reason
Keith Williams Deep Value, special situations, contrarian, Growth
Summary
- Recent report good progress: initial VivaGel (bacterial vaginosis) sales.
- Starpharma receives $3 million milestone payment as DEP-coupled AstraZeneca drug AZD0466 enters a Phase 1 trial in the US for various cancers.
- Starpharma has cash for ~3 years and a pipeline of upcoming announcements in 2020.
- Trading at close to year-low makes this an interesting proposition.
Die Aktie ist immer noch ein Kauf, behaupte ich - langfristig!
Ich bleibe optimistisch. Erhöhe mein Kursziel von 0,88 auf 1,38 €
Die Empfehlung für diese Aktie stammt übrigens von Keith Williams, einem Mann der absolut qualifiziert ist die Erfolgsaussichten dieses australischen Startups einzuschätzen.
... Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering. With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. ...
Die Empfehlung für diese Aktie stammt übrigens von Keith Williams, einem Mann der absolut qualifiziert ist die Erfolgsaussichten dieses australischen Startups einzuschätzen.
... Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering. With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. ...
Kursziel geändert auf 1,8